Evidence map›Paper›PMID 40227827›Full record

ArticleCancers2025

A Comparative Study Between Copy Number Alterations and PRAME Immunohistochemical Pilot Study in Challenging Melanocytic Lesions.

Jeana Chun, Ashley R Scholl, Jennifer Crimmins, Michelle M Schneider, M Angelica Selim, Rami N Al-Rohil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeana ChunSchool of Medicine, Duke University, Durham, NC 27710, USA.
Ashley R SchollDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Jennifer CrimminsDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Michelle M SchneiderDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
M Angelica SelimDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Rami N Al-RohilDepartment of Dermatology, The University of North Carolina Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9431-0530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiagnostic uncertainty for ambiguous lesions that fall on the spectrum between nevi and melanoma remains a significant challenge and can have consequences for patient management.

methodsThis study aimed to compare the diagnostic utility of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry to molecular testing (FISH and SNP array) in 34 diagnostically challenging melanocytic lesions and 9 non-diagnostically challenging melanomas.

resultsWe conclude that while PRAME immunohistochemistry demonstrates high specificity (96.2%) in diagnostically challenging melanocytic lesions, its low sensitivity (12.5%) suggests that it should not replace histopathological evaluation in rendering the final diagnosis.

conclusionsThese findings suggest that PRAME may serve as a useful adjunct in the diagnostic workup, particularly due to its high negative predictive value, but should be used in conjunction with other established diagnostic modalities.

Indexed as

copy number alterationdiagnostically challengingmelanomanevusPRAME

Identifiers

PMID40227827
PMCPMC11988168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.